HDAX Therapeutics novel modality unlocks a never-seen-before binding mechanism to key biological molecules.
Investors 1
Mentions in press and media 2
| Date | Title | Description |
| 05.09.2024 | HDAX Therapeutics Holds First Closing of USD$3.2M Seed Financing | HDAX Therapeutics, a Toronto, Canada-based biotechnology company, held the first closing of a US$3.2M (CA$4.3M) Seed funding.
The round was led by SeedFolio, FACIT, and Toronto Innovation Acceleration Partners, with participation from Eos B... |
| - | HDAX Therapeutics | “HDAX Therapeutics novel modality unlocks a never-seen-before binding mechanism to key biological molecules.” |
Reviews 0
